行情

HZNP

HZNP

Horizon Therapeutics Plc
NASDAQ

实时行情|Nasdaq Last Sale

26.41
-0.26
-0.97%
盘后: 26.41 0 0.00% 16:13 09/18 EDT
开盘
26.71
昨收
26.67
最高
26.71
最低
26.07
成交量
103.93万
成交额
--
52周最高
29.44
52周最低
16.56
市值
49.24亿
市盈率(TTM)
106.23
分时
5日
1月
3月
1年
5年

分析师评级

9位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

HZNP 新闻

  • Horizon Pharma plc (HZNP) Investor Presentation - Slideshow
  • Seeking Alpha - Article.5天前
  • UPDATE: Guggenheim On Horizon Also Notes Potential Catalysts: 'Teprotumumab PDUFA / launch (1Q20), SELB data vs. KKX (4Q19-1Q20), KKX kidney transplant and methotrexate data (2021)'
  • Benzinga.6天前
  • UPDATE: Guggenheim Initiates Horizon With Buy, $36 Target As Firm Believes Co. Is 'EV-103 data at ESMO could hint at larger opportunity in bladder cancer'; Sees 'upside to estimates on Krystexxa /Teprotumumab top line growth (we are modestly above cons.)'
  • Benzinga.6天前
  • Horizon (HZNP) Up 36.7% YTD: Pipeline Development in Focus
  • Zacks.6天前

更多

所属板块

制药
0.00%
制药与医学研究
-0.14%

热门股票

名称
价格
涨跌幅

HZNP 简况

Horizon Therapeutics plc, formerly Horizon Pharma plc, is a rare disease biopharmaceutical company. The Company is focused on researching, developing and commercializing medicines that address needs for people impacted by rare and rheumatic diseases. The Company markets approximately 10 medicines, of which 6 are for rare and rheumatic diseases. The Company's marketed medicines are ACTIMMUNE (interferon gamma-1b), BUPHENYL (sodium phenylbutyrate) Tablets and Powder, DUEXIS (ibuprofen/famotidine), KRYSTEXXA (pegloticase), PENNSAID (diclofenac sodium topical solution) 2% weight per weight (w/w), or PENNSAID 2%, PROCYSBI (cysteamine bitartrate) delayed-release capsules, QUINSAIR (aerosolized form of levofloxacin), RAVICTI (glycerol phenylbutyrate) Oral Liquid, RAYOS (prednisone) delayed-release tablets and VIMOVO (naproxen/esomeprazole magnesium).
展开

Webull提供Horizon Therapeutics PLC的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。